FOXD4L1 Inhibitors
Chemical inhibitors of FOXD4L1 utilize various molecular mechanisms to impede the protein's function. Chetomin targets the hypoxia pathway by disrupting the interaction between hypoxia-inducible factor 1α (HIF-1α) and p300, a coactivator essential for the transcriptional activity of HIF-1α. Since FOXD4L1 can be regulated by HIF-1α, Chetomin's action leads to the reduction of FOXD4L1 activity. Similarly, Echinomycin, a quinoxaline antibiotic, binds to DNA in the minor groove, preventing FOXD4L1 from accessing its DNA binding sites, which are crucial for its role in gene regulation. Another compound, Sunitinib, a tyrosine kinase inhibitor, can inhibit various signaling pathways, potentially affecting the activation status of FOXD4L1. Staurosporine broadly targets protein kinases, which can result in the decreased phosphorylation of FOXD4L1, thereby reducing its regulatory influence on gene expression.
Further inhibitory effects are seen with compounds like PD173074, LY294002, and Wortmannin, which target various kinases and signaling pathways. PD173074 inhibits the fibroblast growth factor receptor (FGFR) pathway, which can lead to reduced activity of downstream transcription factors such as FOXD4L1. LY294002 and Wortmannin both act as PI3K inhibitors, curtailing the phosphatidylinositol 3-kinase pathway, which is involved in regulating FOXD4L1 through downstream signaling molecules. Y-27632, a ROCK inhibitor, could alter cytoskeletal dynamics, thereby affecting the transcriptional control exerted by FOXD4L1. Additionally, SP600125, a JNK inhibitor, and U0126, a MEK1/2 inhibitor, can impair the c-Jun N-terminal kinase and ERK pathways respectively, both of which can influence FOXD4L1's activity. SB203580 targets the p38 MAP kinase pathway, which also has implications for FOXD4L1 function. Lastly, Rapamycin inhibits mTOR signaling, which is a crucial regulator of numerous transcription factors, including FOXD4L1. These inhibitors collectively cover a broad range of signaling pathways and mechanisms, each contributing to the modulation of FOXD4L1's activity within the cell.
SEE ALSO...
Items 1 to 10 of 12 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Chetomin | 1403-36-7 | sc-202535 sc-202535A | 1 mg 5 mg | $186.00 $674.00 | 10 | |
Chetomin disrupts the interaction between hypoxia-inducible factor (HIF) 1α and the transcriptional coactivator p300, leading to reduced transcriptional activity of HIF-1α. Given that FOXD4L1 is a transcription factor that can be regulated by HIF-1α under hypoxic conditions, Chetomin can inhibit FOXD4L1 by decreasing its transcriptional activity mediated by HIF-1α. | ||||||
Quinomycin A | 512-64-1 | sc-202306 | 1 mg | $166.00 | 4 | |
Quinomycin A is a quinoxaline antibiotic that binds to the minor groove of DNA and can inhibit the binding of transcription factors like FOXD4L1 to their cognate DNA sequences, thus inhibiting FOXD4L1's ability to regulate gene expression. | ||||||
Sunitinib, Free Base | 557795-19-4 | sc-396319 sc-396319A | 500 mg 5 g | $153.00 $938.00 | 5 | |
Sunitinib is a tyrosine kinase inhibitor which can lead to the inhibition of downstream signaling pathways that may be involved in the activation of transcription factors including FOXD4L1, thereby reducing its functional activity. | ||||||
Staurosporine | 62996-74-1 | sc-3510 sc-3510A sc-3510B | 100 µg 1 mg 5 mg | $82.00 $153.00 $396.00 | 113 | |
Staurosporine is a potent inhibitor of protein kinases which can inhibit the phosphorylation and thus the activity of a broad range of kinases that are upstream regulators or modulators of transcription factors such as FOXD4L1. | ||||||
PD173074 | 219580-11-7 | sc-202610 sc-202610A sc-202610B | 1 mg 5 mg 50 mg | $47.00 $143.00 $680.00 | 16 | |
PD173074 is an FGFR inhibitor which could inhibit the fibroblast growth factor receptor pathway, potentially resulting in decreased activation of downstream transcription factors such as FOXD4L1. | ||||||
LY 294002 | 154447-36-6 | sc-201426 sc-201426A | 5 mg 25 mg | $123.00 $400.00 | 148 | |
LY294002 inhibits PI3K, which is involved in the AKT signaling pathway. Inhibition of PI3K can lead to reduced activity of downstream targets that may regulate transcription factor activity, including FOXD4L1. | ||||||
Y-27632, free base | 146986-50-7 | sc-3536 sc-3536A | 5 mg 50 mg | $186.00 $707.00 | 88 | |
Y-27632 is a ROCK inhibitor which can inhibit Rho-associated protein kinase, potentially leading to altered cytoskeletal dynamics and reduced activity of transcription factors such as FOXD4L1. | ||||||
SP600125 | 129-56-6 | sc-200635 sc-200635A | 10 mg 50 mg | $40.00 $150.00 | 257 | |
SP600125 is a JNK inhibitor which can inhibit the c-Jun N-terminal kinases pathway, potentially decreasing the activity of transcription factors regulated by this pathway, including FOXD4L1. | ||||||
U-0126 | 109511-58-2 | sc-222395 sc-222395A | 1 mg 5 mg | $64.00 $246.00 | 136 | |
U0126 is an inhibitor of MEK1/2 which can prevent the activation of the ERK pathway, potentially leading to inhibition of downstream transcription factors such as FOXD4L1. | ||||||
SB 203580 | 152121-47-6 | sc-3533 sc-3533A | 1 mg 5 mg | $90.00 $349.00 | 284 | |
SB203580 is a p38 MAPK inhibitor which can inhibit the p38 MAP kinase pathway, potentially leading to decreased activity of transcription factors that are regulated by this pathway, including FOXD4L1. | ||||||